BSE - Delayed Quote INR

Gland Pharma Limited (GLAND.BO)

Compare
1,784.35
-42.95
(-2.35%)
At close: January 10 at 3:29:46 PM GMT+5:30
Loading Chart for GLAND.BO
DELL
  • Previous Close 1,827.30
  • Open 1,790.75
  • Bid 1,778.40 x --
  • Ask 1,781.15 x --
  • Day's Range 1,776.10 - 1,807.00
  • 52 Week Range 1,590.00 - 2,220.95
  • Volume 42,205
  • Avg. Volume 10,615
  • Market Cap (intraday) 293.975B
  • Beta (5Y Monthly) 0.33
  • PE Ratio (TTM) 42.56
  • EPS (TTM) 41.93
  • Earnings Date Feb 13, 2025 - Feb 17, 2025
  • Forward Dividend & Yield 20.00 (1.12%)
  • Ex-Dividend Date Aug 16, 2024
  • 1y Target Est 1,811.92

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. The company engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company offers its products for various therapeutic categories, such as anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastrointestinal, gynaecological, hormones, neuro/Cns, ophthal/otological, and other areas, as well as pain and analgesics, respiratory, and vitamins, minerals, and nutrients; and contract development services. The company was incorporated in 1978 and is headquartered in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.

www.glandpharma.com

4,217

Full Time Employees

March 31

Fiscal Year Ends

Recent News: GLAND.BO

View More

Performance Overview: GLAND.BO

Trailing total returns as of 1/10/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

GLAND.BO
0.10%
S&P BSE SENSEX
1.11%

1-Year Return

GLAND.BO
7.14%
S&P BSE SENSEX
8.39%

3-Year Return

GLAND.BO
53.94%
S&P BSE SENSEX
29.52%

5-Year Return

GLAND.BO
4.90%
S&P BSE SENSEX
86.67%

Compare To: GLAND.BO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: GLAND.BO

View More

Valuation Measures

As of 1/10/2025
  • Market Cap

    293.60B

  • Enterprise Value

    267.56B

  • Trailing P/E

    42.50

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    5.01

  • Price/Book (mrq)

    3.35

  • Enterprise Value/Revenue

    4.56

  • Enterprise Value/EBITDA

    18.29

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    11.74%

  • Return on Assets (ttm)

    5.27%

  • Return on Equity (ttm)

    8.09%

  • Revenue (ttm)

    58.9B

  • Net Income Avi to Common (ttm)

    6.92B

  • Diluted EPS (ttm)

    41.93

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    28.2B

  • Total Debt/Equity (mrq)

    3.72%

  • Levered Free Cash Flow (ttm)

    7.82B

Research Analysis: GLAND.BO

View More

People Also Watch